Search research articles
Contact Us
Filters
Showing results (201-210 of 260) with videos related to
Page
of 26
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2023
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression
Chuandong Geng, Man-Chao Zhang, Ganiraju C Manyam, et al.
JAMA Oncology
|
November 17, 2022
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial
Timothy A Yap, Aditya Bardia, Michael Dvorkin, et al.
NPJ Breast Cancer
|
December 3, 2025
CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen
Nealia C House, Maxine M Chen, Sima Khazaei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2019
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors
Timothy A Yap, Jane N Winter, Lisa Giulino-Roth, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 16, 2024
Outcomes After Palliative Radiation Therapy in Patients With Symptomatic Locoregionally Advanced Breast Cancer
Luisa E Jacomina, David M Swanson, Melissa P Mitchell, et al.
Molecular Cancer Therapeutics
|
December 31, 2010
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930
Timothy A Yap, Mike I Walton, Lisa-Jane K Hunter, et al.
Cancer Discovery
|
March 29, 2024
BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Guang Lei, Chao Mao, Amber D Horbath, et al.
Cancer Research Communications
|
August 27, 2025
Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase 1 Unit
Camila Braganca Xavier, Clark R Andersen, JoAnn Lim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
Timothy A Yap, Matthew G Krebs, Sophie Postel-Vinay, et al.
Nature Reviews. Clinical Oncology
|
January 6, 2026
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology
Amber Johnson, Yifei Shen, Xiaofeng Zheng, et al.
Page
of 26
Search research articles
Search
Showing results (201-210 of 260) with videos related to
Sort By:
Page
of 26
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2023
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression
Chuandong Geng, Man-Chao Zhang, Ganiraju C Manyam, et al.
JAMA Oncology
|
November 17, 2022
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial
Timothy A Yap, Aditya Bardia, Michael Dvorkin, et al.
NPJ Breast Cancer
|
December 3, 2025
CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen
Nealia C House, Maxine M Chen, Sima Khazaei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2019
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors
Timothy A Yap, Jane N Winter, Lisa Giulino-Roth, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 16, 2024
Outcomes After Palliative Radiation Therapy in Patients With Symptomatic Locoregionally Advanced Breast Cancer
Luisa E Jacomina, David M Swanson, Melissa P Mitchell, et al.
Molecular Cancer Therapeutics
|
December 31, 2010
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930
Timothy A Yap, Mike I Walton, Lisa-Jane K Hunter, et al.
Cancer Discovery
|
March 29, 2024
BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Guang Lei, Chao Mao, Amber D Horbath, et al.
Cancer Research Communications
|
August 27, 2025
Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase 1 Unit
Camila Braganca Xavier, Clark R Andersen, JoAnn Lim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
Timothy A Yap, Matthew G Krebs, Sophie Postel-Vinay, et al.
Nature Reviews. Clinical Oncology
|
January 6, 2026
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology
Amber Johnson, Yifei Shen, Xiaofeng Zheng, et al.
Page
of 26